ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer
pharmaphorum
NOVEMBER 16, 2022
has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. RxDx Assay – Roche’s immunohistochemistry (IHC) companion diagnostic for identifying ovarian patients eligible for ELAHERE – has been contemporaneously approved by the FDA. ImmunoGen, Inc.
Let's personalize your content